Joshua Brody Highlights Consensus Statement on Richter Syndrome in Blood Journal
Joshua Brody, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute, shared an article by Adam S Kittai et al. on LinkedIn, adding:
“Richter Syndrome still a huge unmet need in CLL and Lymphoma, here’s a coherent consensus statement by world-expert Adam S Kittai”
Dr. Joshua Brody shared a recent publication from Blood (2025) authored by Adam S. Kittai and colleagues, titled “Richter Transformation of Chronic Lymphocytic Leukemia: Consensus Recommendations from an International Expert Panel.”. The article presents comprehensive expert recommendations for diagnosing and managing Richter Syndrome, a challenging and high-risk transformation of CLL. The consensus highlights current gaps in clinical care and offers guidance to improve patient outcomes through standardized approaches.
Title: International Consensus Statement on Diagnosis, Evaluation, and Research of Richter Transformation: the ERIC Recommendations
Authors: Adam S Kittai, et al
Journal: Blood, April 2025
More posts featuring Joshua Brody.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023